Replies to post #91353 on Biotech Values

[dewophile]

re achn 1625

500 bid should be amenable to coformulation, particularly if the second compound has an even lower dose. if it ends up as a QD formulation and they need 1g a day it's not going to be easy though, especially if it ends up as a 3 drug combination
but those are alot of what ifs, and i do think the achn compound is potent enough to be coformulated (but not as potent as idx 320) so i stand corrected